China's 3SBio acquired ex-China rights (it already owned China rights) for an anti-TNF mAb aimed at rheumatoid arthritis from Apexigen of San Francisco; Materialise of Belgium opened a multidisciplinary 3D printing center in Beijing's Fuwai Hospital to aid in difficult cardiovascular surgeries; Ascletis, a Hangzhou-US pharma, said China and Taiwan accepted a CTA to test its dual-drug, interferon-free regimen for hepatitis C, a first in China; BeiGene of Beijing was granted FDA approval to start US clinical trials of a BTK inhibitor for B-cell malignancies; Taiwan's PharmaEngine reported its pancreatic cancer drug candidate was granted priority review in the US and earned a $11 million milestone for a European filing; and SGS Life Science Services expanded its microbiology testing lab in Shanghai.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
